Mylan
Executive Summary
Richard Moldin is appointed president and chief operating officer, effective April 3. He will succeed Milan Puskar, who remains chairman & CEO. Moldin was previously CEO of Faulding's U.S. oral pharmaceuticals business and was succeeded by Frank Condella, who took over Feb. 1 after serving as VP-national specialty care business at Roche